Etrasimod

Last Updated: 04/28/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 135 publications

Efficacy and Safety of Etrasimod in Moderate-To-Severe Ulcerative Colitis: A GRADE-Based Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Efficacy and Safety of Etrasimod in Moderate-To-Severe Ulcerative Colitis: A GRADE-Based Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Journal: The Annals of pharmacotherapy

Published: March 27, 2026

Etrasimod: A Next-Generation S1P Receptor Modulator for Ulcerative Colitis - Mechanistic Insights and Clinical Progress.

Etrasimod: A Next-Generation S1P Receptor Modulator for Ulcerative Colitis - Mechanistic Insights and Clinical Progress.

Journal: Zhongguo ying yong sheng li xue za zhi = Zhongguo yingyong shenglixue zazhi = Chinese journal of applied physiology

Published: February 03, 2026

Etrasimod Treatment Modulates Circulating and Lymph Node-Derived Lymphocytes in Crohn's Disease.

Etrasimod Treatment Modulates Circulating and Lymph Node-Derived Lymphocytes in Crohn's Disease.

Journal: International journal of molecular sciences

Published: January 21, 2026

Effectiveness of etrasimod on disease activity and patient-reported outcomes in ulcerative colitis-EFFECT-UC: a non-interventional, multinational, prospective cohort study protocol.

Effectiveness of etrasimod on disease activity and patient-reported outcomes in ulcerative colitis-EFFECT-UC: a non-interventional, multinational, prospective cohort study protocol.

Journal: BMJ open

Published: December 25, 2025

Autotaxin Induces S1P/S1PR1 Signaling to Affect Th17/Treg Cell Balance and Exacerbate Intestinal Inflammation in Colitis.

Autotaxin Induces S1P/S1PR1 Signaling to Affect Th17/Treg Cell Balance and Exacerbate Intestinal Inflammation in Colitis.

Journal: International journal of molecular sciences

Published: December 04, 2025

Sphingosine 1-Phosphate (S1P) Receptor Modulators as an Induction and Maintenance Therapy for Moderate to Severe Ulcerative Colitis: A Systematic Review and Meta-analysis of Randomized Controlled Trials.

Sphingosine 1-Phosphate (S1P) Receptor Modulators as an Induction and Maintenance Therapy for Moderate to Severe Ulcerative Colitis: A Systematic Review and Meta-analysis of Randomized Controlled Trials.

Journal: Digestive diseases and sciences

Published: December 02, 2025

Etrasimod: Review of the safety and practical management considerations of a new oral therapy for the treatment of ulcerative colitis.

Etrasimod: Review of the safety and practical management considerations of a new oral therapy for the treatment of ulcerative colitis.

Journal: Gastroenterologia y hepatologia

Published: October 13, 2025

Rapid symptomatic improvement with etrasimod in ulcerative colitis: a post-hoc analysis of the ELEVATE UC program.

Rapid symptomatic improvement with etrasimod in ulcerative colitis: a post-hoc analysis of the ELEVATE UC program.

Journal: Inflammatory bowel diseases

Published: September 24, 2025

A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for etrasimod.

A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for etrasimod.

Journal: Frontiers in pharmacology

Published: August 26, 2025

Sphingosine-1-Phosphate (S1P) Receptor Modulators for the Treatment of Inflammatory Bowel Disease (IBD): Mechanisms, Clinical Evidence, and Practical Insights.

Sphingosine-1-Phosphate (S1P) Receptor Modulators for the Treatment of Inflammatory Bowel Disease (IBD): Mechanisms, Clinical Evidence, and Practical Insights.

Journal: Biomedicines

Published: August 20, 2025

A narrative review on the frequency, pathophysiology and management of bowel urgency associated with ulcerative colitis.

A narrative review on the frequency, pathophysiology and management of bowel urgency associated with ulcerative colitis.

Journal: Best practice & research. Clinical gastroenterology

Published: August 08, 2025

Tregs going acid - how cholestasis impairs regulatory T cell function.

Tregs going acid - how cholestasis impairs regulatory T cell function.

Journal: Journal of hepatology

Published: July 29, 2025

Showing 1-12 of 135

Last Updated: 04/28/2026